---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-001895"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:55:38.725494+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CEO John Jacobs resigns; CMO Jeffrey Dayno named Interim CEO; Jeff Aronin becomes Executive Chairman

## Summary
- CEO John C. Jacobs resigns effective Jan 20, 2023 to pursue another opportunity; no disagreement with Company.
- Jeffrey M. Dayno, current CMO, appointed Interim CEO effective Jan 6, 2023; will remain CMO.
- Founder and Board Chairman Jeffrey S. Aronin appointed Executive Chairman to provide oversight during transition.
- Board expresses confidence in underlying business and strategic execution.

## SEC filing metadata
- accession: 0001104659-23-001895
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000110465923001895/0001104659-23-001895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000110465923001895/tm232529d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-001895
- JSON: https://secwatch.observer/filing/0001104659-23-001895.json
- Plain text: https://secwatch.observer/filing/0001104659-23-001895.txt

## Key facts
- Executive change
  Jeffrey M. Dayno was appointed as Interim Chief Executive Officer at Harmony Biosciences Holdings, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: On January 6, 2023, the Board appointed Dr. Jeffrey M. Dayno, the Company’s current Chief Medical Officer, as the Company’s Interim Chief Executive Officer, effective January 6, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000110465923001895/0001104659-23-001895-index.htm
- Executive change
  John C. Jacobs resigned as President and Chief Executive Officer at Harmony Biosciences Holdings, Inc..
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: On January 6, 2023, Harmony Biosciences Holdings, Inc. (the “Company”) announced that John C. Jacobs is resigning as President and Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000110465923001895/0001104659-23-001895-index.htm
- Executive change
  Jeffrey S. Aronin was appointed as Executive Chairman at Harmony Biosciences Holdings, Inc..
  - Action: appointed
  - Role: Executive Chairman
  source text: On January 6, 2023, in connection with Mr. Jacobs’ resignation from the Board and to provide additional support and oversight during this transition period, the Board appointed Jeffrey S. Aronin, currently Chairman of the Board, as the Company’s Executive Chairman, effective January 6, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000110465923001895/0001104659-23-001895-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.